Sapm Report (pancholi chirag)
-
Upload
pancholi-chirag -
Category
Documents
-
view
247 -
download
0
Transcript of Sapm Report (pancholi chirag)
-
7/31/2019 Sapm Report (pancholi chirag)
1/67
ECONOMIC ANALYSIS
-
7/31/2019 Sapm Report (pancholi chirag)
2/67
1.GDP:
Gross domestic product (GDP) is the measure of national income. Its trend shows the
actual picture of countrys economy. It is a measure of wealth and health of economy.
India is one of the fastest growing economies in world today. Everybody is looking at
India. Its GDP is higher than most countries in the world.
Source: CMIE
The Goldman Sachs has projected long term trend in GDP, which is
expected to be higher than other developing countries like china and Brazil.
-
7/31/2019 Sapm Report (pancholi chirag)
3/67
Above is the long term forecast of GDP we can see that GDP of India
is expected to grow at a consistent rate where as mighty Chinese GDP is expected to fall
in coming years and will remain around 2%.
2.MONSOON AND AGRICULTURAL PRODUCTION :
India is an agriculturist country. More than 70% of population of India depends on
agriculture for their livelihood. And Indian agriculture depends mainly on monsoon
because there is no proper irrigation infrastructure. If monsoon is below average it can
negatively affect Indian economy at large. So, monsoon has direct impact on
performance of any industry. The trend of monsoon over the years and its relationship
with GDP has been given below:
From chart we can see that both lines move simultaneously in same
direction. So, there is a strong relationship between monsoon and growth in GDP. But
our agriculture production depends upon rain there are no proper irrigation facilities, if
India wants to be world leader than it should have irrigation infrastructure.
-
7/31/2019 Sapm Report (pancholi chirag)
4/67
Total Foodgrain production is expected to remain 220 Mn tons which is
5% more than previous year with projected rainfall of 80%.
Table: Foodgrain production versus monsoons
Exhibit: Total Foodgrain production in the country
-
7/31/2019 Sapm Report (pancholi chirag)
5/67
3.SAVING AND INVESTMENT
The latest estimates for saving and capital formation pertain to 2003-04.The CSOs quick
estimates indicate that the rate of Gross Domestic Saving (GDS) rose to 24.2 per cent of
GDP at current market prices in 2003-04, entirely due to reduction in the public sectors
dis-saving. Households - the mainstay of overall saving in the economy - recorded a
decline in terms of financial saving which, in turn, marginally reduced the rate of
household sector saving. There was also a marginal decline in the rate of private
corporate sector saving in 2003-04.
-
7/31/2019 Sapm Report (pancholi chirag)
6/67
4.INDUSTRIAL PERFORMANCE
The strengthening of industrial growth in India was broad-based and occurred in an
environment of accelerating industrial activity in various parts of the world, especially in
East Asian economies. External demand embodied in exports provided a boost to a
spectrum of manufacturing industries, supported by improvement in domestic demand
conditions and reductions in excise duties on a
host of intermediate inputs.
Growth of Index of Industrial Production
The CSOs advance estimates indicate a distinct pick-up in the growth
of real GDP originating in industry from the second quarter that was sustained in the third
quarter of 2003-04. The upturn was evident as early as May 2003 in terms of the index of
industrial production (IIP) (Chart). Over the period April 2003-February 2004, industrial
production rose faster than in the preceding year on account of higher growth in the
manufacturing sector .The CSO has placed the growth of real GDP originating in
manufacturing at 7.1 per cent in 2003-04 as against 6.2 per cent in the preceding year.
-
7/31/2019 Sapm Report (pancholi chirag)
7/67
5.INFLATON
High inflation can adversely affect Indian economy. It is a high inflation period in India
due to increase in crude oil prices in international market and below average monsoon in
India this year.
Exhibit: inflation during July-August 2004
inflation (WPI) in july-August 2004
7.617.96 7.94
8.17
7
7.5
8
8.5
31-Jul 07-Aug 14-Aug 21-Aug
week ended
percent
Source: RBI
Inflation, measured in movement in wholesale price index (WPI), has
increased from 7.61% during week ended 31 July to 8.17% during week ended 21.
August 2004.rising crude oil price in the international market is the min reason behind
the recent spurt in inflation. In the mean time government has shown its sincerity in
containing inflation within manageable limit.
High inflation discourages deposits especially long term. Because the
real increase in deposit will be negligible if there is high inflation. So, people invest their
money in mutual funds and stock market to earn higher return.
-
7/31/2019 Sapm Report (pancholi chirag)
8/67
6.CURRENT ACCOUNT
As in the preceding two years, the invisible surplus was able to fully offset the
merchandise trade deficit. The surplus in the invisible account increased from US $ 12.6
billion in April-December 2002 to US $ 18.2 billion in April-December 2003, mainly on
account of higher receipts from software services, private transfer receipts and tourism
earnings. A revival of international interest in India as a tourist destination was reflected
in an increase of 18.5 per cent in tourist arrivals in 2003-04. Exports of software and IT-
enabled services have been growing at an average rate of 46 per cent since the mid-
1990s. Despite the global slowdown, Indian IT industry raised its share in global IT-
spending from about one per cent at the end of the 1990s to about three per cent
currently. India is one of the most preferred destinations for outsourcing of IT services.
With buoyant invisible receipts, the current account surplus increased to US $ 3.2 billion
during April-December 2003 from US $ 2.9 billion during the corresponding period of
the previous year
Exhibit: Current Account Balance
-
7/31/2019 Sapm Report (pancholi chirag)
9/67
6.STOCK MARKET
Recently there is a bullish trend in stock market. Sensex is going to touch 6000 points.
Most of the shares are at their historic high positions. Investors confidence in stock
market has increased. They expect this trend to persist for a long time. This also has
boosted new issues in primary market. This has affected positively all industry. People
has attracted toward direct investment in shares as they are giving higher return than any
other investment opportunity. Mutual funds are performing best, so all these factors have
contributed toward fall in deposits.
Primary Market trends:
After a long period of lacklustre activity, the public issues market experienced a
revival. Resource mobilisation in the public issues market (excluding offers for
sale) amounted to Rs.7,190 crore through 35 issues during 2003-04, as against only
Rs.4,867 crore raised through 17 issues during 2002-03 (Chart 53). Out of the
issues floated in 2003-04, 28 were equity issues accounting for 40.5 per cent of
resource mobilisation. Public sector entities accounted for 55.4 per cent of total
resources mobilised in the primary market.
Trend in Public issue
01000200030004000500060007000
1997
-98
1998
-99
1999
-200
0
2000
-01
2001
-02
2002
-03
2003
-04
Public issue(Pvt. Sector) Public issue(Public sector)
Non-Government public limited companies (private sector) garnered
Rs.3,210 crore through 27 issues during 2003-04 as compared with Rs.1,878 crore raised
through nine issues during the previous year. In 2003-04, 24 equity issues aggregated to
Rs.1,959 crore as compared with five equity issues aggregating Rs.460 crore during the
-
7/31/2019 Sapm Report (pancholi chirag)
10/67
previous year. Equity issances surged during the second half of 2003-04 (Chart 54).
There were three debt issues of Rs.1,251 crore (all from ICICI Bank) during 2003-04 as
compared with four bond issues of Rs.1,418 crore during 2002-03.
7.INTEREST RATE
By monetary policy 2004-05 RBI kept interest rate unchanged at 6%. Before that Interest
rate was decreasing. This will lead to increase in demand for loans because if the loans
are available at cheaper rate then people will ask for more loans to make investments.
-
7/31/2019 Sapm Report (pancholi chirag)
11/67
-
7/31/2019 Sapm Report (pancholi chirag)
12/67
INDUSTRY ANALYSIS: PHARMACEUTICAL
INTRODUCTION:
The Indian pharmaceutical industry, which was operating in a
protectionist regime, is now gearing to face competition emerging from product patents
in a WTO era. Pharmaceuticals being essential items for humans, the industry is
protected from cyclical fluctuations.
The shift towards product patent era in 2005 has made the domestic
industry conscious of the need to increase expenditure in Research. Hence, the market
leaders' earnings are likely to show consistent growth, but for temporary aberrations
resulting from increased R&D and global marketing expenses. However, globally as well
as domestically, the industry is witnessing large-scale mergers and acquisitions, that will
have drastic implications for the Indian market.
With quality human resources, low cost of research and world wide
opportunities, the industry is keen on replicating the success of IT in the global pharma
industry.
The Indian Pharmaceutical industry is highly fragmented with about 10,000
manufacturing units (300 in the organized sector). The top ten companies make up
for more than third of the market. The revenues generated by the industry are
approximately US$ 5 bn and growing at an average rate of 9% over last five years.
While formulations account for around 35% of this industry, bulk drugs make up for
the balance. The Indian pharma industry accounts for about 1% of the world's pharma
industry in value terms and 8% in volume terms, which suggest that it has a huge
potential to grow in value term. However, the annual per capita drug expenditure is
still amongst the lowest in the world.
Per Capita Health Per 1000 people
-
7/31/2019 Sapm Report (pancholi chirag)
13/67
Expenditure (US$)
India 94 0.8
Brazil 453 3.1
China 143 2.9
Malaysia 189 2
USA 3950 3.7
Source: World Bank
In recent past Indian companies have targeted international markets and have extended
their presence there. While some companies are doing bulk drug exports some have
moved up in the value chain and export formulations and generic products. The total
exports from the country stood at Rs 141 bn in the year 2003. The country also offers
excellent exports opportunities for clinical trials, R&D, custom synthesis, technical
services like Bioinformatics.
The drug price control order (DPCO) continues to be a menace for the industry. The
pricing authority arbitrarily sets prices of drugs that fall within its ambit without giving
due consideration even to the costs of production. There are three tiers of regulations -on
bulk drugs, on formulations and on overall profitability. This has made the profitability of
the sector susceptible to the whims and fancies of the pricing authority. Consequently,
MNCs show reluctance in launching patented drugs from their parent's product portfolio,
thereby, affecting their market share. Although government has brought down the DPCO
cover from 74 to 25 drugs in the new DPCO, the same has not been brought into effect due
to impending litigation. However, once implemented, this could increase profitability of
companies having relatively older portfolios, particularly MNCs.
INDUSTRY STRUCTURE:
The industry comprises about 18000 players, of which 250 leading
players control almost 70% of the market. The domestic formulation market grew by
modest 6.3% to Rs 18212 crore in the twelve months ended Feb'03 as per ORG MAT
-
7/31/2019 Sapm Report (pancholi chirag)
14/67
Feb'03. The growth rate in the industry has come down considerably from around 16% in
the 90's particularly in view of the hectic competition from generic generics.
Domestic players account for over 70% market share and the rest is
accounted for by MNCs. The leading domestic companies are Dr. Reddy's
Laboratories (DRL), Ranbaxy Laboratories (RLL), Sun Pharmaceuticals, Cipla, Lupin
Laboratories, Orchid Chemicals and Wockhardt while the leading MNCs are
Glaxosmithkline, Pfizer, Aventis Pharma and Merck India.
If one considers the entire healthcare scenario, allopathy accounts for
50% of the overall Indian market, ayurveda accounts for 30% and sidha, unani, homeo
and other systems share the rest.
Financial Year '04
FY04 was relatively a good year for the markets in India for domestic and to extent
MNC pharma companies also. ON back of low growth rate last the market grew by
about 7.3% this year in value terms. However, severe competition led to significant
price erosion to an extent of 2%, which led to lower growth in value term.
Commoditisation of the domestic pharma market severely impacted the anti-infective
segment, which grew only by 5%. The point to note here is that anti-infective segment
constitutes about 17% of the pharma market. However, new product launches
contributed significantly in the growth of the market.
In view of the intense competition in the domestic markets, Indian pharma majors are
increasingly tapping the export market for growth. Export revenues now contribute
more than two third of the revenues of Dr. Reddy's and about 80% of the revenues of
Ranbaxy. Apart from export of formulations and bulk drugs, Indian companies have
also entered into contract manufacturing. Though exports are providing growth impetus
and size to Indian majors, it will be a while before Indian majors can make their
presence felt in the global markets.
-
7/31/2019 Sapm Report (pancholi chirag)
15/67
The research initiatives of the pharma industry have been commendable. It is not only
the majors who are committing substantial research efforts but also the comparatively
smaller companies like Glenmark, Lupin and Cadila. The country now boasts of several
state of the art pharma research centers dedicated to basic research.
PROSPECTS:
While FY04 recorded a good growth and the markets grew by about 7.3% mainly
driven by high growth in lifestyle segment such as CVS (17%), CNS (9%), anti-
diabetic (12%) and respiratory (9%) therapeutic segments. However, intense
competition ensured that the values of the products to decline. In fact the growth in
volume terms was about 2% more than growth in value terms. In the year while
Indian companies performed very well both in exports as well as the domestic
markets, performance of the MNC's was not very impressive. However, in the longer
run, Indian companies would face fresh competition from MNCs, as they would make
aggressive new launches once product patents are recognized post 2005.
The DPCO is likely to be significantly diluted soon though there is litigation pending
over it in supreme court. In case the new order is passed the pressure on pricing of
MNC pharma products is likely to go away. Companies with high DPCO coverage
currently and strong brands in place are expected to benefit.
The penetration of health insurance is abysmally low in the country. The entry of
private players would not only bring in quantum leap in the health insurance business
-
7/31/2019 Sapm Report (pancholi chirag)
16/67
but also increase capital inflows into this sector. With drug prices expected to increase
post 2005, health insurance could provide a cushion against it and thus maintain the
demand for drugs.
On the exports front, the global generics market is growing at the rate of 10% to 12%and drugs having estimated sales of over US$ 55 bn expected to go off patent in the
next few years. This coupled with the fact that the US government is facilitating a
speedy introduction of generic drugs into the market, increasing the number of
generics drugs in its Mediclaim policy, bodes well for generic exporters. However the
opportunity here may not be as big as stated above, because the prices fall drastically
once the drug goes off patent.
CRITICAL SUCCESS FACTORS:
Investment in R & D (especially basic research), an extensive
distribution network and marketing strategies, new product introductions, penetration into
global generics markets, effective anti-dumping duties, logistics management and brand
building are critical.
Compliance with international GMP is critical to expand the marketsbeyond the domestic market. Likewise, compliance with domestic GMP, which will
become mandatory from Dec'03 will be critical for sustaining in the domestic market.
Domestic pharma companies which target global generics and in US in
particular, have to gain vast expertise to challenge the patent holders, that are likely to
take the generic firms to court, just to protect their patents even after their expiry.
Likewise, innovations are also likely to be challenged before court, and the home grown
companies need to specialise and gain expertise in dealing not only with chemicals but
also on and off the court, to reap benefits from their research.
-
7/31/2019 Sapm Report (pancholi chirag)
17/67
DEMAND DRIVERS :
An increase in coverage (currently at 35% of the population), opening
up of health insurance, becoming global sources for MNCs and the growing global
generics segment are demand drivers. An increase in health consciousness and growingadvertising and marketing efforts by corporates will boost the demand for the OTC
segment. Lifestyle diseases are increasing at a fast pace, consequent to the fast changing
life style of Indians.
The huge and growing generics opportunity and the regulatory
compliance by domestic firms have resulted in wider acceptability of pharma products
from India, as could be guaged by increased exports. Hence, low cost quality production
and regulatory compliance have also become demand drivers for the domestic industry,
for increased pharma exports.
Pharma: Through Porters eyes
Today's business environment is extremely competitive and in
economics parlance where perfect competition exists, the profits of the firms operating in
that industry will become zero in long run. However, this is not possible because, firstlythere is no perfect competition and no company is a passive price taker (i.e. no company
will operate where profits are zero). Secondly, they strive to create a competitive
advantage to thrive in the competitive scenario. Michael Porter, considered to be one of
the foremost gurus of management, developed the famous five-force model, which
influences an industry. In this article, we apply this model for the Indian pharma industry.
-
7/31/2019 Sapm Report (pancholi chirag)
18/67
INDUSTRY COMPETITION:
Pharma industry is one of the most competitive industries in the country with as many as
10,000 different players fighting for the same pie. The rivalry in the industry can be
gauged from the fact that the top player in the country has only 6% market share, and the
top five players together have about 18% market share. Thus, the concentration ratio for
this industry is very low. High growth prospects make it attractive for new players to
enter in the industry.
Another major factor that adds to the industry rivalry is the fact that theentry barriers to pharma industry are very low. The fixed cost requirement is low but the
need for working capital is high. The fixed asset turnover, which is one of the gauges of
fixed cost requirements, tells us that in bigger companies this ratio is in the range of 3.5
to 4 times. For smaller companies, it would be even higher.
-
7/31/2019 Sapm Report (pancholi chirag)
19/67
Many smaller players that are focused on a particular region, have a
better hang of the distribution channel, making it easier to succeed, albeit in a limited
way. An important fact is that pharma is a stable market and its growth rate generally
tracks the economic growth of the country with some multiple (1.2 times average in
India). Though volume growth has been consistent over a period of time, value growth
has not followed in tandem.
The product differentiation is one key factor, which gives
competitive advantage to the firms in any industry. However, in pharma industry product
differentiation is not possible since India has followed process patents till date, with laws
favouring imitators. Consequently, product differentiation is not the driver, cost
competitiveness is. However, companies like Pfizer and Glaxo have created big brands in
over the years, which act as product differentiation tools. This will enhance over the long
term, as product patents come into play from 2005.
BARGAINING POWER OF BUYERS:
The unique feature of pharma industry is that the end user of the product is different from
the influencer (read Doctor). The consumer has no choice but to buy what doctor says.
However, when we look at the buyer's power, we look at the influence they have on the
prices of the product. In pharma industry, the buyers are scattered and they as such does
not wield much power in the pricing of the products. However, government with its
policies, plays an important role in regulating pricing through the NPPA (National
Pharmaceutical Pricing Authority).
BARGAINING POWER OF SUPPLIERS:
The pharma industry depends upon several organic chemicals. The chemical industry is
again very competitive and fragmented. The chemicals used in the pharma industry are
largely a commodity. The suppliers have very low bargaining power and the companies
in the pharma industry can switch from their suppliers without incurring a very high cost.
-
7/31/2019 Sapm Report (pancholi chirag)
20/67
However, what can happen is that the supplier can go for forward integration to become a
pharma company. Companies like Orchid Chemicals and Sashun Chemicals were
basically chemical companies, who turned themselves into pharmaceutical companies.
BARRIERS TO ENTRY:
Pharma industry is one of the most easily accessible industries for an entrepreneur in
India. The capital requirement for the industry is very low, creating a regional
distribution network is easy, since the point of sales is restricted in this industry in India.
However, creating brand awareness and franchisee amongst doctors is the key for long-
term survival. Also, quality regulations by the government may put some hindrance for
establishing new manufacturing operations. Going forward, the impending new patent
regime will raise the barriers to entry. But it is unlikely to discourage new entrants, as
market for generics will be as huge.
THREAT OF SUBSTITUTES:
This is one of the great advantages of the pharma industry. Whatever happens, demand
for pharma products continues and the industry thrives. One of the key reasons for high
competitiveness in the industry is that as an on going concern, pharma industry seems to
have an infinite future. However, in recent times, the advances made in the field of
biotechnology, can prove to be a threat to the synthetic pharma industry.
CONCLUSION
This model gives a fair idea about the industry in which a company operates and the
various external forces that influence it. However, it must be noted that any industry is
not static in nature. It's dynamic and over a period of time the model, which have used to
analyse the pharma industry may itself evolve.
Going forward, we foresee increasing competition in the industry but
the form of competition will be different. It will be between large players (with
-
7/31/2019 Sapm Report (pancholi chirag)
21/67
economies of scale) and it may be possible that some kind of oligopoly or cartels come
into play. This is owing to the fact that the industry will move towards consolidation. The
larger players in the industry will survive with their proprietary products and strong
franchisee. In the Indian context, companies like Cipla, Ranbaxy and Glaxo are likely to
be key players. Though consolidation within the current big names is not ruled out.
Smaller fringe players, who have no differentiating strengths, are likely to either be
acquired or cease to exist.
The barriers to entry will increase going forward. The change in the
patent regime, will see new proprietary products coming up, making imitation difficult.
The players with huge capacity will be able to influence substantial power on the fringe
players by their aggressive pricing which will create hindrance for the smaller players.Economies of scale will play an important part too. Last but not the least, in a vast
country of Indias size, government too will have bigger role to play.
Indian Pharma Industry: SWOT analysis
It is often said that the pharma sector has no cyclical factor attached toit. Irrespective of whether the economy is in a downturn or in an upturn, the general
belief is that demand for drugs is likely to grow steadily over the long-term. True in some
sense. But are there risks? This article gives a perspective of the Indian pharma industry
by carrying out a SWOT analysis (Strength, Weakness, Opportunity, Threat).
Before we start the analysis lets look a little back in the industrys last
six years performance. The Industry is a largely fragmented and highly competitive with
a large number of players having interest in it. The following chart shows the breakup of
the growth (YoY) of Indian pharmaceutical industry in last six years.
-
7/31/2019 Sapm Report (pancholi chirag)
22/67
*Volume growth of existing products
The SWOT analysis of the industry reveals the position of the Indian
pharma industry in respect to its internal and external environment.
Strengths:
1. Indian with a population of over a billion is a largely untapped market. In fact the
penetration of modern medicine is less than 30% in India. To put things in
perspective, per capita expenditure on health care in India is US$ 93 while the same
for countries like Brazil is US$ 453 and Malaysia US$189.
2. The growth of middle class in the country has resulted in fast changing lifestyles in
urban and to some extent rural centers. This opens a huge market for lifestyle drugs,
which has a very low contribution in the Indian markets.
3. Indian manufacturers are one of the lowest cost producers of drugs in the world.
With a scalable labor force, Indian manufactures can produce drugs at 40% to 50%
of the cost to the rest of the world. In some cases, this cost is as low as 90%.
-
7/31/2019 Sapm Report (pancholi chirag)
23/67
4. Indian pharmaceutical industry posses excellent chemistry and process
reengineering skills. This adds to the competitive advantage of the Indian
companies. The strength in chemistry skill help Indian companies to develop
processes, which are cost effective.
Weakness:
1. The Indian pharma companies are marred by the price regulation. Over a period of
time, this regulation has reduced the pricing ability of companies. The NPPA
(National Pharma Pricing Authority), which is the authority to decide the various
pricing parameters, sets prices of different drugs, which leads to lower profitability
for the companies. The companies, which are lowest cost producers, are at
advantage while those who cannot produce have either to stop production or bear
losses.
2. Indian pharma sector has been marred by lack of product patent, which prevents
global pharma companies to introduce new drugs in the country and discourages
innovation and drug discovery. But this has provided an upper hand to the Indian
pharma companies.
3. Indian pharma market is one of the least penetrated in the world. However, growth
has been slow to come by. As a result, Indian majors are relying on exports for
growth. To put things in to perspective, India accounts for almost 16% of the world
population while the total size of industry is just 1% of the global pharma industry.
4. Due to very low barriers to entry, Indian pharma industry is highly fragmented with
about 300 large manufacturing units and about 18,000 small units spread across the
country. This makes Indian pharma market increasingly competitive. The industry
witnesses price competition, which reduces the growth of the industry in value
term. To put things in perspective, in the year 2003, the industry actually grew by
-
7/31/2019 Sapm Report (pancholi chirag)
24/67
10.4% but due to price competition, the growth in value terms was 8.2% (prices
actually declined by 2.2%)
Opportunities
1. The migration into a product patent based regime is likely to transform industry
fortunes in the long term. The new patent product regime will bring with it new
innovative drugs. This will increase the profitability of MNC pharma companies
and will force domestic pharma companies to focus more on R&D. This migration
could result in consolidation as well. Very small players may not be able to cope up
with the challenging environment and may succumb to giants.
2. Large number of drugs going off-patent in Europe and in the US between 2005 to
2009 offers a big opportunity for the Indian companies to capture this market. Since
generic drugs are commodities by nature, Indian producers have the competitive
advantage, as they are the lowest cost producers of drugs in the world.
3. Opening up of health insurance sector and the expected growth in per capita income
are key growth drivers from a long-term perspective. This leads to the expansion ofhealthcare industry of which pharma industry is an integral part.
4. Being the lowest cost producer combined with FDA approved plants, Indian
companies can become a global outsourcing hub for pharmaceutical products.
Threats:
1. There are certain concerns over the patent regime regarding its current structure. It
might be possible that the new government may change certain provisions of the
patent act formulated by the preceding government.
-
7/31/2019 Sapm Report (pancholi chirag)
25/67
2. Threats from other low cost countries like China and Israel exist. However, on the
quality front, India is better placed relative to China. So, differentiation in the
contract manufacturing side may wane.
3. The short-term threat for the pharma industry is the uncertainty regarding the
implementation of VAT. Though this is likely to have a negative impact in the
short-term, the implications over the long-term are positive for the industry.
POLITICAL-LEGAL FACTORS:
There are so many government rules and regulations for
pharmaceutical industries in India. Government has played supportive role in the
development of pharmaceutical industry in India. Because pharma products is basic or
necessity for human beings. As Indian population touches to 120 crores in these days it is
very necessary product. There are so many ways pharma industry can be affected by
political and legal factors.
1.LIBRALISATION POLICY:
Through libralisation policy 1991, government made it easy for private companies
to start their business by deregulation and delicencing measures. Now, There is
need for few statutory requirement to start a pharma company. so any person with
-
7/31/2019 Sapm Report (pancholi chirag)
26/67
limited capital and expertise and skill can start new business. Government also
provides many types of facilities for new entrepreneur.
2. Goverment has established many special economic zones where pharma
companies are provided with infrastructural facilities like rail, road, drainage,
desposal of hazards, etc. with tax holiday for some period. So any existing
company can expand their business because all supported facilities are available at
one place with tax benefits .
3 multinational companies are allowed to carry on their business &Indian companies
can globally compete. There are so many multinational companies in India are
working because they see India or big market place . there is no competition for
pharma company.
TAX STRUCTURE:
Pharmaceutical companies have to pay excise sales tax and corpate
tax according to law. But they pass all this to their customer as this is necessity
&no perfect subsidies is available customer pay price.
ECONOMICAL FACTOR:
1) High inflation rate negatively affect pharmaceutical industrys life saving
drugs become costlier people tend to be consume less. Even if they are
unavoidable & basic basic commodity the demand is negatively
2) Insurance protection can positively affect pharmaceutical industry. People
have enough money to spend on. It there was no insurance and if any major
surgery is to be taken place turn and people can not afford & get died.
3) Compare to develop countries people spent less proportion of their income on
health.
-
7/31/2019 Sapm Report (pancholi chirag)
27/67
4) Saving can positively affect Parma industry if people have enough saving they
can afford costly treatment and get well soon many people died off due to
improper treatment while in critical situation.
5) 70% of Indian population depends on agriculture for their livelihood. There is no
proper infrastructure for irrigation so people have to depend on rain. If monsoon
remain below average then people will suffer and try to spend less on their health
by using home made medicine.
SOCIO-CULTURAL FACTORS:
1) Demographic: its population explosion in India population of India is increasing at
a accelerated rate and is compounding. Population touches 120 crores it is a matter
of serious concern for any economy but pharma industry gain positively because it
is necessity to survive.
2) Culture, Taboo, Customs of India are so strong and prosperous. They affect
adversely. Indian culture is oldest one it has Vedas . Means how to maintain good
health how to cure your disease and people have been using there for themselves
effectively.
3) In India there are still many village where doctors have not reached there .so,
people treat their daises by traditional way by using home made medicine& taking
treatment from vidhya. A traditional professional person who cures people &
without getting degree.
4) People of India are very religious especially in village. They take bhoova & leave
everything on god pledge for quickly recovery.
5) Literacy level in India is very low compare to developed country. People do not
know effectiveness of medicine and put more trust on traditional way of curing
disease.
-
7/31/2019 Sapm Report (pancholi chirag)
28/67
6) life style of people of India is very poor . They spend less too many on their health.
CEMENT
INTRODUCTION
One of the oldest of brick and mortar industries, the Indian cement sector is now hogging
the limelight as leading players are gearing to face the new economy. The cement sector
has undergone a veritable metamorphosis after the decontrol. Further, it witnessed a
blistering pace of growth in the succeeding years and now the industry is estimated to
have a turnover of Rs 25,000 crore.
Virtually thrown open to market forces, the sector stands witnesses to
large-scale consolidation moves via acquisitions, mergers or hostile takeovers. However,
the domestic players appear to have successfully scuttled the MNC players from playing
a greater role in the domestic cement industry. Aditya Birla group will eventually emerge
-
7/31/2019 Sapm Report (pancholi chirag)
29/67
as the largest player in the domestic cement industry, with the proposed take over of the
cement business of Larsen & Toubro. Earlier, Gujarat Ambuja had acquired 14.43%
strategic stake in ACC. In the process, Grasim Industries will control about 22% of the
domestic large plant capacity while Gujarat Ambuja will control about 20%. As a result,
these two players alone control over 42% of the capacity of large cement plants in India.
The Indian cement industry with a total capacity of 144 m tonnes (including mini plants)
in FY04, has surpassed developed nations like USA and Japan and has emerged as the
second largest market after China. Although consolidation has taken place in the Indian
cement industry with the top six players controlling almost 60% of the capacity, the
remaining 40% of the capacity remains pretty fragmented with around 40 players in the
fray.
Despite the fact that Indian cement industry has clocked a production of more than 100 m
tonnes for the second year in succession, the per capita consumption of 110 kgs
compares poorly with the world average of 260 kgs. This, more than anything underlines
the tremendous scope for growth in the Indian cement industry in the long term.
Cement, being a bulk commodity, is a freight intensive industry and transporting cement
over long distances can prove to be uneconomical. This has resulted in cement being
largely a regional play with the industry divided into five main regions viz. north, south,
west, east and the central region. While the southern region is excess is capacity owing to
the availability of limestone, the western and northern region are the most lucrative
markets. Therefore, players like Grasim, L&T and Gujarat Ambuja enjoy high price
realisations compared to the all India average.
Given the high potential for growth, quite a few foreign transnationals have been eyeing
the Indian markets and are planning to acquire domestic companies. Already companies
like Lafarge and Italicementi have made a couple of acquisitions and other majors like
Holcim and Cemex are waiting for a favorable opportunity to do the same. However, the
transnationals will find the going tough since cement is a game of volumes and with the
median capacity of fragmented players being just about 1 m tonne, the transnationals will
-
7/31/2019 Sapm Report (pancholi chirag)
30/67
have to acquire capacities piecemeal and this route is fraught with a lot of uncertainties.
Although the government has reduced the import duty on cement, imports do not pose a
threat since prices of cement in India are lower than those prevailing in the international
markets. Moreover, the storage facilities on the Indian ports are inadequate for large-scale imports.
Financial Year '04In FY04, the cement sector grew at a slower rate of 5.5% as compared to 8% last year
owing to prolonged monsoons, which affected cement demand in the first half of the
fiscal year. To put things in perspective, in 1HFY04, the cement sector grew by an
estimated 4.4% as compared to almost 7.1% in 2HFY04. As is evident from the graph
below, after a slower growth in revenues in the first half of the fiscal, the second half of
the year witnessed a recovery. Cement prices also followed suit.
Although the demand grew by only 5.5% y-o-y, there was a 5% growth in industry
realisation owing to the fact that the demand-supply situation is slowly improving. The
price realisation also has to be viewed in the context of additional supply of around 2
MT with the commissioning of the Sanghi Cement facility. Had the demand grown at a
faster rate, the improvement in price realisation would have higher. In effect, we
believe that FY04 was a positive year for the industry.
While cement prices, on a YoY basis, were higher by around 5% for the industry, the
rise in prices was higher in the western and the northern region as compared to the
southern market. The pricing scenario is relatively unfavorable in the southern market
given the fact that this region has an excess capacity of close to 11 MT, the highest
-
7/31/2019 Sapm Report (pancholi chirag)
31/67
among all the regions in the country.
PROSPECTS:
The industry is likely to maintain its growth momentum and continue growing at
around 8% in the medium to long term. Government initiatives in the infrastructure
sector (such as the commencement of second phase of NHDP, rural roads, 10,000 kms
of additional highways as announced in Finance Budget) and the housing sector are
likely to be the main drivers of growth for the industry.
The acquisition of L&T's cement division by Grasim has changed the landscape of the
entire cement industry and in one fell swoop has catapulted Grasim to the leadership
position. This is a healthy sign for the industry, as this would result in consolidation
and would give significant pricing power to the bigger players. With consolidation
taking place at the lower end also, the unviable units will be forced to shut down thus
benefiting the long-term interests of the industry.
With no major capacity expansion in the pipeline, the demand supply level is expected
to achieve parity on a macro level by FY07 and this will help in the improvement of
prices. However, since the level of demand supply mismatch is higher in the southern
region, it will take longer to achieve demand supply parity.
The industry worked at estimated 84% capacity in FY04 and given the current growth
rates and also assuming no major capacity expansion in the near future, the capacity
utilisation is likely to go up significantly in the future. This will help in improving the
margins of all the major players and will lead to higher profitability.
-
7/31/2019 Sapm Report (pancholi chirag)
32/67
Despite these positives, the possibility of interest rates heading north and the
consequent impact on housing demand remains to be seen. While infrastructure
spending was a boon, there was a strong cushion from the steady growth of the
construction sector. the hike in prices of coal and petroleum products could impact
cement companies margins (account for around 40% of sales). Though the pricing
cushion exists, the margin rise will be mitigated to this extent.
CRITICAL SUCCESS FACTORS:
Better cost control, lowering debt-equity ratio caused by funding of
acquisitions and Greenfield projects primarily through borrowings and better capacity
utilization is critical success factors. Freight and transport costs being significant in
cement industry, efficient logistics management is equally critical.
With power and fuel costs exceeding 21% of the sales, units with
captive power plants have a distinct advantage. This is particularly because of unreliable
supply from SEBs that comes at a huge cost, as against reliable and relatively low cost
captive power plants.
With growing interests shown by MNCs in the Indian market, the
competitive milieu is shifting towards companies with deep pockets who can absorbtemporary losses.
DEMAND DRIVERS
Indias per capita consumption is about 90 kg compared to the world
average of 250 kg. This implies great growth potential for the domestic industry. With60% of the demand coming from the housing sector, the fortunes of cement industry are
closely linked to it. The soft interest rates prevailing in the country, and ever increasing
need for housing and easy availability of finance have enabled strong growth in the
housing construction sector, thereby leading to improved demand for cement.
-
7/31/2019 Sapm Report (pancholi chirag)
33/67
Further, the huge investment flows into the roadways and highway
projects have stimulated demand growth for the cement industry. The roadways and
highways project in general, and the golden quadrilateral project in particular, has
generated significant demand for cement in the last couple of years and continues to
propel demand for FY 2002-03 also.
Greater thrust on continued investments in new infrastructure projects
like ports, roads and highways will power the demand growth for cement for next few
years. With nearly Rs. 8,00,000 crore worth of investments likely in electricity generation
in the coming decade, the overall prospects of the growth in demand appears bright.
Of late, exports are also increasing at impressive rates. The
export of cement and clinker, together, rose from 3.14 million tonne in 1999-00 to
6.92 million tonne in 2002-03. The cement and clinker exports grew by impressive
37.8% in two months ended May03 to 1.35 million tonne. If the tempo of growth
is maintained, the industrys cement and clinker exports can even cross 8 million
tonne in the current year.
-
7/31/2019 Sapm Report (pancholi chirag)
34/67
PORTERS FIVE FORCE ANALYSIS:
Supply There is an oversupply situation in the industry due to capacity additions
by the major players in the industry. The situation is likely to improve,
as there is no major Greenfield expansion in sight.
Demand Housing sector acts as the principal growth driver for cement. However,
in recent times, industrial and infrastructure sector have also emerged as
demand drivers for cement.
Barriers to entry High capital costs and long gestation periods. Access to limestone
reserves (principal raw material for the manufacture of cement) also acts
as a significant entry barrier.
Bargaining
power of
suppliers
Licensing of coal and limestone reserves, supply of power from the state
grid and availability of railways for transport are all controlled by a
single entity, which is the government.
Bargaining
power of
customers
Cement is a commodity business and sales volumes mostly depend upon
the distribution reach of the company. However, things are changing and
few brands such as Gujarat Ambuja and L&T have started commanding
a premium on account of better quality perception.
Competition Due to large number of players in the industry and very little brand
differentiation to speak of, the competition is intense with players
resorting to frequent price cuts in order to gain market share.
-
7/31/2019 Sapm Report (pancholi chirag)
35/67
COMPANY ANALYSIS
-
7/31/2019 Sapm Report (pancholi chirag)
36/67
ABBOTT INDIA
BASIC INFORMATION:
Incorporation year 1949
Ownership Private (Foreign)
Main activity Drug formulations
HISTORY:
Abbott India Ltd (formerly known as Knoll Pharmaceuticals Ltd) is one of the largest
MNC Pharma company operating in India. The company has presnt in both OTC drugs and
formulations(dosage form). Further it has also have a number of best selling and well
known brands in its portfolio. Digene, Creamafin and Brufen are some examples.
The company incorporated in 1944 became the subsidiary of Knoll AG,
Germany following the integration of the Pharmaceutical activities of Boots worldwide
with those of BASF, Germany(the parent company of Knoll AG). Subsequent to this the
name of the company has got changed to Knoll Pharmaceuticals from Boots
Pharmaceuticals. Abbott Laboratories based in Illinois, USA acquired the pharma business
of BASF South East Asia Pvt Ltd on Dec 2000. Abbott Laboratories have increase its stake
in the company to 58.2 % by acquiring another 7.2% via mandatory open offer made to theIndian public. The name of the company has also changed to Abbott India Ltd w.e.f July
2002. .
Knoll Pharma's revenues largely come from insulin and formulation
sales. In fact, the biggest contribution comes from insulin, where the company has a
-
7/31/2019 Sapm Report (pancholi chirag)
37/67
marketshare of over 60%. Other products like Brufen and Digene are leaders in their
respective therapeutic segments. Besides these, the CNS (central nervous system) range is
one of Knoll's core focus areas. It has also launched Ganaton,own research product for
gastric motility disorders, in 2001-02. The company has commenced marketing various
products such as Lucrin,Norvir,Klacid IV,Forane and Sevorane,which are imported from
the parent company. .
The company is in the process of amalgamating its wholly owned
subsidiary Lenbrook Pharmaceuticals Ltd with itself. It has obtained the approval of H'ble
High Court of Bombay for its scheme of amalgamation.
BOARD OF DIRECTORS:
NAME POSITION
Munir Shaikh CH
D M Gavaskar MD & President
R A Shah Director
Thomas Chen DirectorDavid Wardell Director
Ashok Dayal Director
G S Kurmi Co. Secretary
EQUITY HOLDING INFORMATION:
-
7/31/2019 Sapm Report (pancholi chirag)
38/67
Type/Name of holder No of shares % of total
shares
Foreign Promoters
Lupharma UK Holding One Ltd 82,62,000 54.07Abbott Equity Holdings Ltd 11,66,184 7.63
Mutual Funds And Uti
Unit Trust of India 3,35,100 2.19
BANKS,FI'S,INSURANCE COS.
National Insurance Company Ltd 8,11,806 5.31
Life Insurance Corporation of India 2,34,766 1.54
United India Insurance Company Ltd 1,69,514 1
About 54% of the shares of Abbott are held by Lupharma UK Holding
One Ltd which is UK based Company. UTI has about 2% holding and insurance companies
hold about 8% of total shares. Mutual funds have not purchased this companys shares.
This may be weak side otherwise fundas of this company is very good. It is consistently
increasing its scope in Indian market.
FUND FLOW ANALYSIS:
200311 200211 200111 200012 199912
-
7/31/2019 Sapm Report (pancholi chirag)
39/67
Sources of funds
Cash profit 70.61 61.16 52.66 75.27 71.59
Increase in other networth 0 1.5 1.06 0 0
Increase in loan funds 0 0 0 1.76 0
Decrease in gross block 0 0.36 0 0 0
Decrease in investments 0 0 0 47.22 0
Decrease in working capital 36.6 4.86 0 0 66.11
Total Inflow 107.21 67.88 53.72 124.25 137.7
Application of fund:
Decrease in networth 34.45 0 0 21.59 5.62
Decrease in loan funds 0.15 0.03 1.66 0 0.18
Increase in gross block 0.69 0 1.91 1.05 1.87
Increase in investments 18.44 48.41 3.96 0 64.42
Increase in working capital 0 0 29.99 28.71 0
Dividend 53.48 19.44 16.2 72.9 65.61
Others 0 0 0 0 0
Total Outflow 107.21 67.88 53.72 124.25 137.7
INTERPRETATION OF FUND FLOW STATEMENT:
Profit of the company is increasing at a consistent rate. It was 52.66 crores in 2001, Rs.
61.16 Cr. In year 2002 and was increased by Rs.9.45 Cr.to Rs.70.61Cr. in the fiscal year
-
7/31/2019 Sapm Report (pancholi chirag)
40/67
2003. so. Cash profit is increasing at 15% every year. On the other hand companys
investmet has decreased. In the year 2002 investment was Rs.48 crores which was
decreased to 18 in the previous year. It means company is not finding enough investment
opportunities and its distributing most of earnings to its shareholders in the form of
dividends.
So, company need to find good investment opportunities. It should
invest in increase its scope rather than distributing as dividends.
CASH FLOW ANALYSIS:
Abbott India Ltd.
Dec
1999
Dec
2000
Nov
2001
Nov
2002
Nov
2003
Rs. Crore (Non-Annualised) 12 mths 12 mths 11 mths 12 mths 12 mths
-
7/31/2019 Sapm Report (pancholi chirag)
41/67
Net profit before tax & extra ord.
Items 46.37 71.51 64.57 84.77 95.06
Add: depreciation 5.09 5.33 4.48 5.32 4.39
Interest payable 0.32 1.46 0.12 0.12 0.1
Gain or loss on forex
transactions 0 0.03 -0.01 0.01 0
Write offs / amortisation 0 0 0 0 0
Profit on sale of investments -0.63 -18.45 -5.69 -3.62 -11.28
Profit on sale of assets -0.38 -0.24 -0.27 -0.72 0.18
Interest income -1.2 0 0 0 0
Dividend income 0 -3.48 -2.06 -0.84 -2.86
Other income / provision
adjustments 0.44 0.51 0.01 0.15 0.67
-
Cash flow before working cap.Changes 50.01 56.67 61.15 85.19 86.26
Trade receivables 23.56 -1.59 -1.75 -1.7 1.46
Inventories 1.11 -16.45 4.28 9.29 14.35
Trade payables 9.26 19.55 -16.56 -6.2 -16.97
Others 0 0 0 0 0
-
Cash flow from operations 83.94 58.18 47.12 86.58 85.1
Interest paid -0.32 -1.46 -0.12 -0.12 -0.1
Direct taxes paid -12.99 -13.84 -13.43 -22.4 -30.57
Dividend tax paid 0 0 0 0 0
-Cash flow before extra ord. items 70.63 42.88 33.57 64.06 54.43
Extraordinary items 0 0 0 0 0
-
Cash flow from operating
activities 70.63 42.88 33.57 64.06 54.43
-
Net cash used in investing
activities -60.49 79.89 2.43 -47.13 -1.6
Purchase of fixed assets -3.54 -3.07 -2.09 -6.46 -2.31
Sale of fixed assets 6.08 13.82 0.73 3.28 0.31
Acquisition / merger of cos. 0 0 0 0 0
Purchase of investments -93.89 -123.01 -57.76 -148.39 -204.29
Sale of investments 29.66 188.67 59.49 103.6 201.83
Dividend received 1.2 3.48 2.06 0.84 2.86
Other income 0 0 0 0 0
-
7/31/2019 Sapm Report (pancholi chirag)
42/67
Net cash used in financing
activities -11.64 -126.67 -26.78 -16.23 -53.04
Proceeds from share issues 0 0 0 0 -32.2
Total proceeds from
borrowings 0 0 0 0 0Proceeds from long term
borrowings 0.05 0 0 0 0
Proceeds from short term
borrowings 0 0 0 0 0
Repayment of long term
borrowings 0 0.1 0 -0.03 -0.15
Repayment of short term
borrowings 0 0 0 0 0
Share issue expenses 0 0 0 0 0Dividend paid -11.69 -126.77 -26.78 -16.2 -20.69
Other cash from financing
activities 0 0 0 0 0
-
Net cash flow -1.5 -3.9 9.22 0.7 -0.21
-
Opening cash balance 6.17 4.67 0.77 9.99 10.69
Closing cash balance 4.67 0.77 9.99 10.69 10.48
INTERPRETATION OF CASHFLOW ANALYSIS:
The cash flow analysis show the liquidity position of the firm. The profit of the company is
in dec 99 is 46.37 cr. Ids increase to 95.06 cr. In November 2003 the cash flow before
working capital IN NOV. 99 is 50.01 cr. Is increased in nov. 2003 is to 86.26 the cash flow
from operation is 83.26 cr. In dec. 99 is increased to 85.26 in nov. 2003.
-
7/31/2019 Sapm Report (pancholi chirag)
43/67
RATIO ANALYSIS:
Profitability Ratios % Period EndedDec2003
(11 Months)
Period EndedDec2002
(9 Months)
Period EndedMar2002
(12 Months)
Operating Profit Margin -22.93 -3.02 4.84
Gross Profit Margin -23.53 -1.74 5.14
Net Profit Margin -24.97 -4.42 3.53
Inventory Turnover Ratio 3.60 2.97 8.59
Debtor Turnover Ratio 8.92 6.39 12.19
Fixed Asset TurnoverRatio 2.17 2.63 5.55
Current Ratio 1.64 2.59 2.52
DebtEquity Ratio 0.71 0.02 0.00
Interest Covering Ratio -11.78 -12.39 21.95
Return On Investment -18.00 -4.00 13.00
Return On Networth -33.00 -5.00 9.00
Dividend Yield 0.00 0.00 0.00
Debt Equity Ratio 71.00 2.00 0.00
-
7/31/2019 Sapm Report (pancholi chirag)
44/67
PROFIT AND LOSS A/C
. PeriodEnded
Mar2004
% PeriodEnded
Mar2003
%
Sales 5018.82 +98.65 2556.39 +99.54Other Income 68.60 +1.35 11.91 +0.46
Total Income 5087.42 2568.30
Raw Material Cost 2553.67 +50.20 1216.69 +47.37
Excise 290.28 +5.71 208.22 +8.11
Other Expenses 631.67 +12.42 501.29 +19.52
Operating Profit 1611.80 +31.68 642.11 +25.00
Interest Name 31.71 +0.62 50.58 +1.97
Gross Profit 1580.10 +31.06 591.53 +23.03
Depreciation 138.53 +2.72 120.17 +4.68
Profit Bef. Tax 1441.56 +28.34 471.36 +18.35
Tax 228.08 +4.48 118.53 +4.62
Net Profit 1213.49 +23.85 352.82 +13.74
Other Non-Recurring Income 33.24 +0.65 5.91 +0.23
Reported Profit 1246.73 +24.51 358.73 +13.97
Equity Dividend 100.00 +1.97 0.00 0.00
-
7/31/2019 Sapm Report (pancholi chirag)
45/67
BALANCE SHEET
LIABILITIES
PeriodEnded
Mar2004
PeriodEnded
Mar2003
PeriodEnded
Mar2001
Share Capital 500.00 18.38 15.00
Reserves & Surplus 4,916.31 1,248.72 565.10
Net Worth (1) 5,416.31 1,267.10 580.10
Secured Loans (2) 646.91 685.65 343.00
Unsecured Loans (3) 0.00 0.00 38.90
Total Liabilities (1+2+3) 6,063.23 1,952.75 962.00
ASSETS
PeriodEnded
Mar2004
PeriodEnded
Mar2003
PeriodEnded
Mar2001
Gross Block 1,912.29 1,555.46 786.70
(-) Acc. Depreciation 471.20 335.56 164.10
Net Block (A) 1,441.09 1,219.90 622.60
Capital Work in Prgs. (B) 543.12 79.84 25.20
Investments (C) 89.33 84.83 0.60
Inventories 839.52 466.96 217.60
Sundry Debtors 1,159.64 737.47 391.70Cash And Bank< 3,175.11 10.22 0.10
Loans And Advances 287.27 156.84 59.90
(i) 5,461.54 1,371.48 669.30
Current Liabilities 1,329.09 777.58 355.70
Provisions 142.77 25.72 0.00
(ii) 1,471.86 803.30 355.70
Net Curr. Assets (i - ii) (D) 3,989.68 568.18 313.60
Misc. Expenses (E) 0.00 0.00 0.00Total Assets (A+B+C+D+E) 6,063.23 1,952.75 962.00
-
7/31/2019 Sapm Report (pancholi chirag)
46/67
BIOCON
BASIC INFORMATION:
Incorporation year 1978
Ownership Private (Foreign)
Main activity Bio-tech base drugs
Subsidiary/ies Biocon Biopharmaceuticals Pvt. Ltd.
Clinigene International Pvt. Ltd.
Syngene International Pvt.
Ltd.
HISTORY:
Biocon is India's largest biotech company with a presence in bio-pharmaceuticals,
enzymes, customs research and clinical research. Chairman Kiran Mazumdar Shaw
promoted the company as a joint venture with Ireland-based MNC Biocon Biochemicals.
Later, Unilever Plc acquired Biocon Biochemical's stake in February 1995, but sold it to
the current promoters in June 1999. .
Kiran Mazumdar Shaw is a first generation entrepreneur with over 25
years of experience in biotechnology. She is the recipient of several awards, the most
noteworthy being the Padmashri, conferred in 1989; the Ernst & Young Entrepreneur of the
Year Award in 2002 for the Healthcare & Lifesciences category; and, more recently, in
2003, the BioSpectrum Person of the Year award. She heads several biotechnology task-
forces including the Karnataka Vision Group on Biotechnology, an initiative by the
government of Karnataka, and the National Taskforce on Biotechnology for the
Confederation of Indian Industry. .
Key management personnel of the company include Arun Bhardwaj,
-
7/31/2019 Sapm Report (pancholi chirag)
47/67
Arun Chandavarkar and Shrikumar Suryanarayanan, apart from Mr and Mrs Shaw. Arun
Bhardwaj is the group's marketing president and has nearly 20 years of experience in direct
marketing, sales and strategy and served as project engineer in Max India prior to joining
Biocon. Dr Chandavarkar is the group's president - manufacturing and has over 13 years of
experience in manufacture and scale-up of fermentation process, projects, maintenance and
quality assurance. Suryanarayanan is the group's R & D president with about 20 years of
experience in research of fermentation-based manufacturing techniques and was
instrumental in the company's R & D functions. .
Biopharmaceuticals (biopharma) and enzymes together constitute about
90 to 93% of the group revenues. But Biocon has been progressively increasing the share
of biopharma from 61% in FY 2001 to 64% in FY 2002 to 71% in FY 2003 and to 81% in
the nine months ended December 2003 in the total group revenues.
Biopharmaceuticals has been and will continue be the mainstay of
Biocon it promise exciting growth opportunities. This segment is involved primarily in
manufacture and marketing of active pharmaceutical ingredients (API) that require
advanced fermentation and other skills and offer significant market potential in the
regulated markets once the product goes off patent. Within this segment, statins constitute
major products. Statins are a group of popular cholesterol-lowering drugs.
The significant growth in sales in the recent past has resulted in full
utilisation of capacity in the existing manufacturing facilities. A number of generic
companies who are in the process of registering their formulations in the US and Europe
for sale (upon expiry of patents) have evinced interest to use Biocon's statins. The company
has already filed 8 drug master files in the US and 7 in the Europe for its various products.
To cater to this increased demand, it plans to invest Rs 413.4 crore over a period of time up
to FY2006 towards setting up a new fermentation and chemical synthesis facility as a
100% EOU. .
In March 2004, the company tapped the capital market through 100%
-
7/31/2019 Sapm Report (pancholi chirag)
48/67
book building method. The IPO comprises of 10 million equity shares of Rs 5 each with a
price band of Rs.270 -Rs.315 per equity share. The proceeds from the book building will be
utilised for setting up a new facilities and chemical synthesis operations with an estimated
fund of Rs.413.40 crores.
BOARD OF DIRECTORS:
NAME POSITION
Kiran Mazumdar-Shaw CH & MD
John Shaw Vice CHNeville Bain (Dr.) Director
Charles L Cooney (Prof.) Director
Suresh Talwar Director
Ravi Mazumdar (Prof.) Director
Catherine Rosenberg (Prof.) Director
Ada K H Tse (Ms.) Director
FUND FLOW STATEMENT:
200403 200303 200203
-
7/31/2019 Sapm Report (pancholi chirag)
49/67
SOURCES OF FUNDS
Cash profit 138.47 47.82 41.68
Increase in equity 48.16 0.02 1.82
Increase in other networth 252.41 3.39 63.39
Increase in loan funds 0 2.1 66.46Decrease in investments 0 0 0
Decrease in working capital 0 0 0
Total Inflow 439.04 53.33 173.35
APPLICATION OF FUNDS
Decrease in networth 0 0 0
Decrease in loan funds 3.87 0 0
Increase in gross block 82.25 33.94 127.17
Increase in investments 0.45 0 8.48
Increase in working capital 342.15 19.12 37.7Dividend 10 0 0
Others 0.32 0.27 0
Total Outflow 439.04 53.33 173.35
INTERPRETATION OF FUND FLOW:
Cash profit of the company was about Rs. 138 Crores which is thrice than previous year. It
means company has enough liquidity. But still it did not find good investment
opportunities. In the previous year company made investment of Rs.45 lacs. only. there
was huge increase in working capital of the company, it was increased to Rs. 342.15 Crores
in the financial year 2003-04 from Rs. 19.12 crores in the year 2002-03.
RATIO ANLYSIS:
Profitability Ratios % Period EndedDec2003
(11 Months)
Period EndedDec2002
(9 Months)
Period EndedMar2002
(12 Months)
Operating Profit Margin -22.93 -3.02 4.84
Gross Profit Margin -23.53 -1.74 5.14
Net Profit Margin -24.97 -4.42 3.53
Inventory Turnover Ratio 3.60 2.97 8.59
Debtor Turnover Ratio 8.92 6.39 12.19
Fixed Asset TurnoverRatio 2.17 2.63 5.55
Current Ratio 1.64 2.59 2.52
-
7/31/2019 Sapm Report (pancholi chirag)
50/67
DebtEquity Ratio 0.71 0.02 0.00
Interest Covering Ratio -11.78 -12.39 21.95
Return On Investment -18.00 -4.00 13.00
Return On Networth -33.00 -5.00 9.00
Dividend Yield 0.00 0.00 0.00Debt Equity Ratio 71.00 2.00 0.00
P& L A/C
. PeriodEnded
Dec2003
(11Mnts.)
% PeriodEnded
Dec2002
(9Mnts.)
% PeriodEnded
Mar2002
%
Sales 300.02 +98.67 414.25 +98.50 991.96 +99.48
Other Income 4.05 +1.33 6.30 +1.50 5.22 +0.52
Total Income 304.07 420.56 997.18
Raw Material Cost 179.84 +59.14 250.78 +59.63 490.11 +49.15
Excise 32.15 +10.57 8.63 +2.05 60.66 +6.08
-
7/31/2019 Sapm Report (pancholi chirag)
51/67
Other Expenses 156.84 +51.58 167.36 +39.80 393.23 +39.43
Operating Profit -64.75 -21.29 -6.21 -1.48 53.18 +5.33
Interest Name 5.84 +1.92 1.01 +0.24 2.18 +0.22
Gross Profit -70.59 -23.21 -7.22 -1.72 51.00 +5.11
Depreciation 14.62 +4.81 7.89 +1.88 10.56 +1.06Profit Bef. Tax -85.21 -28.02 -15.12 -3.59 40.44 +4.06
Tax -10.28 -3.38 3.18 +0.76 5.37 +0.54
Net Profit -74.93 -24.64 -18.30 -4.35 35.06 +3.52
Other Non-Recurring Income
-42.17 -13.87 -6.82 -1.62 -22.90 -2.30
Reported Profit -117.09 -38.51 -25.12 -5.97 12.16 +1.22
Equity Dividend 0.00 0.00 0.00 0.00 0.00 0.00
BALANCE SHEET
LIABILITIES
PeriodEnded
Dec2003(11
Mnts.)
PeriodEnded
Dec2002(9
Mnts.)
PeriodEnded
Mar2002(12
Mnts.)Share Capital 26.10 26.10 26.10
Reserves & Surplus 199.74 321.22 346.34
Net Worth (1) 225.83 347.31 372.44
Secured Loans (2) 4.00 6.96 0.00
Unsecured Loans (3) 155.94 0.64 0.96
-
7/31/2019 Sapm Report (pancholi chirag)
52/67
Total Liabilities (1+2+3) 385.77 354.91 373.40
ASSETS
PeriodEnded
Dec2003(11
Mnts.)
PeriodEnded
Dec2002(9
Mnts.)
PeriodEnded
Mar2002(12
Mnts.)
Gross Block 229.33 233.66 257.99
(-) Acc. Depreciation 90.82 76.42 79.13
Net Block (A) 138.52 157.24 178.86
Capital Work in Prgs. (B) 0.00 3.29 3.29
Investments (C) 0.00 0.00 0.15
Inventories 102.58 143.71 109.86
Sundry Debtors 33.62 64.85 81.35
Cash And Bank< 4.77 1.23 73.44
Loans And Advances 70.18 106.79 51.95
(i) 211.14 316.58 316.60
Current Liabilities 125.33 117.14 117.23
Provisions 3.65 5.07 8.27
(ii) 128.98 122.21 125.50
Net Curr. Assets (i - ii) (D) 82.16 194.38 191.10
Misc. Expenses (E) 165.09 0.00 0.00
Total Assets (A+B+C+D+E) 385.77 354.91 373.40
ACC
BASIC INFORMATION:
Incorporation year 1936
Ownership ACC Group
Main activity Cement
Subsidiaries A C C Machinery Co. Ltd.
A C C-Nihon Castings Ltd.
-
7/31/2019 Sapm Report (pancholi chirag)
53/67
Bargarh Cement Ltd.
Bulk Cement Corpn. (India) Ltd.
Cement Marketing Co. Of India
Damodhar Cement & Slag Ltd.
Everest Industries Ltd.
HISTORY:
Associated Cement Companies (ACC), one of the leading Cement producer in
India came into existence consequent to the amalgamation of ten cement
companies in 1936. Manufacturing and marketing of cement, redymix concrete,
refractories and refractory products are the main business of ACC. Further the
company is also into consultancy and engineering services.ACC's manufacturing
base consists 14 cement plants spread well all over India, two refractory plants one
each at maharashtra and MP and 6 RMC plants near to four metros of India and
Bangalore. The total cement capacity of ACC stands at 161.47 lakh tonnes at
March 31, 2003. .
In Jan. 1999, the company came out with a rights issue to fund its
capex projects involving modernisation/ expansion of existing plants and creation
of new capacity at Wadi. The company meets around 83% of its power
requirements from its captive power plants. The captive power plant at Jamul and
Kymore with an capacity of 25 MW each was commissioned in Nov 1999. The 15
MW capitive powerplants at Chanda, Tikaria and Madukkarai were commissioned
during the year 2002-03. .
-
7/31/2019 Sapm Report (pancholi chirag)
54/67
In 2000, Tata group has exited from the company by divesting
their 14% equity stake in favour of Gujarat Ambuja group. Notably, Gujarat
Ambuja group is the most efficient and aggressive cement group in India. The
disinvestment was done in phases at Rs 370 per share. ACC has completed themodernization and expansion of the Chanda and Madukkarai cement plants for
increasing their capacities to around 1 MTPA each. These plants started
production from 1 September 2000 and 1 October 2000 respectively. The de-
bottlenecking at Chanda, Gagal and Madukarrai plants have added 1 MT to ACC's
installed capacity. The 2.6 MTPA Cement plant at Wadi with largest Kiln in the
country has started its commercial production from Oct 2001.
The company has decided to exit from the non-core businesses in
an optimal manner. The company has completed divestment of its stake in
Floatglass India Ltd([13% stake] in 2001-02), International Ferrites Ltd.([35%
stake] in 2002-03) and Bridgestone ACC India Ltd.([19% stake] in 2002-03).
Further it has also sold its stake(5,00,000 E.Shares) in Tata Industries in 2001-02.
The company is making all efforts to hive off the ACC Nihon Casting, a 100%
subsidiary of ACC manufacturing alloy steel casting but has not met success yet.
.
At the same time of existing from non-core businesses the
company has not failed to invest in core activities it has acquired 76.01% stake in
Eternit Everest from Etex Group in Feb 2002. Consequent to the acquisition the
Eternit everest became the subsidiary of ACC w.e.f from Feb 12, 2002.
-
7/31/2019 Sapm Report (pancholi chirag)
55/67
-
7/31/2019 Sapm Report (pancholi chirag)
56/67
OARD OF DIRECTORS / KEY PERSONNEL:
NAME POSITION
Tarun Das CH
Narotam Sekhsaria Deputy CH
M L Narula MD
A K Jain Exec. Director
N A Soonawala Director
O P Dubey Director
A L Kapur Director
Cyril S Shroff Director
Amitabha Ghosh Director
A Anjeneyan Director (UTI)
Naresh Chandra Co. Secretary
R K Vashishtha Director
EQUITY HOLDING INFORMATION:
Banks, FIIs and mutual fund companies have holdings in ACC.
This shows that this is considered to be fundamentally strong company and it has
good prospects. They have about 35% of total holding in this company. So, it is
horse of long race. Every professional institution is keeping eyes on this company.
-
7/31/2019 Sapm Report (pancholi chirag)
57/67
EQUITY HOLDING INFORMATION:
Type/Name of holder No of shares % of total
shares
MUTUAL FUNDS AND UTI
HSBC Equity Fund 31,32,771 1.76
UTI - Master Share Unit Scheme 18,31,622 1.03
BANKS,FI'S,INSURANCE COS.
Life Insurance Corporation of India 2,84,49,758 15.97
New India Assurance Company Ltd 33,33,612 1.87
Oriental Insurance Company Ltd 22,49,247 1.26
FII'S
Small Cap World Fund Inc 71,50,000 4.01HSBC Global Investment Funds A/c 56,93,500 3.2
Government of Singapore Investment
Corporation Pte Ltd 26,22,675 1.47
Capital Research & Management
Company A/C New World Fund Inc 25,00,000 1.4
Merrill Lynch Capital Markets Espana
SA SVB 19,17,207 1.08
PRIVATE CORPORATE BODIES
Ambuja Cement India Ltd 2,46,70,000 14
ANY OTHER
Shares underlying GDRs 28,50,000 1.6
Shares held by Pakistani Citizens 3,85,965 0.22
FUND FLOW STATEMENT:
200403 200303 200203 200103 200003
SOURCES OF FUNDS
Cash profit 345.95 265.36 289.87 174.75 58.8
Increase in equity 6.27 0.14 0.11 0 34.04
Increase in other net worth 140.83 0 0 5.56 147.24
-
7/31/2019 Sapm Report (pancholi chirag)
58/67
Increase in loan funds 0 0 0 231.62 49.8
Decrease in investments 0 47.57 6.14 0 0
Decrease in working Capital 49.81 104.94 278.47 3.72 53.71
Others 17.23 21.44 0 17.15 0
Total Inflow 560.09 439.45 574.59 432.8 343.59
APPLICATION OF FUNDS
Decrease in net worth 0 4.38 211.23 0 0
Decrease in loan funds 78.94 92.11 130.65 0 0
Increase in gross block 162.3 300.23 177.93 387.9 253.19
Increase in investments 247.97 0 0 9.27 25.49
Increase in working capital 0 0 0 0 0
Dividend 70.88 42.73 51.24 34.14 15.65
Others 0 0 3.54 1.49 49.26
Total Outflow 560.09 439.45 574.59 432.8 343.59
Fund flow statement is very useful to know application of funds in particular period
and also from where those funds came.
Cash profit of the company is increasing at a consistent rate. In the
year 2003-04 the cash profit of the company was Rs. 345.95 Cr. Increase in net
worth was RS. 140.83 Cr. In the financial year 203-04 there was decrease in
working capital. These were sources of funds.
Company also paid back its loan of Rs.78.94 Cr. And paid dividend to
its shareholders in current financial year due to increase in net cash profit. So, company is
earning good cash profit and repaying its long-term obligations. Company has also
invested Rs. 248 Crores. And a company has enough investing opportunities.
-
7/31/2019 Sapm Report (pancholi chirag)
59/67
CASH FLOW STATEMENT:
200403 200403 200303 200303 200203
Cash Flow Summary
Cash and Cash Equivalents at
Beginning of the year 34.82 27.49
Net Cash from Operating Activities 478.29 442.04
Cash Flow From Operating Activities
Net Profit before Tax & Extraordinary
Items 264.16 135.14 200.33
Adjustment For
Depreciation 176.85 164.56 151.14
Interest (Net) 92.91 103.91 139.95
Dividend Received -37.6 -0.39 0
P/L on Sales of Assets -4.38 -5.19 -2.74P/L on Sales of Invest 0.05 -50.36 -9.13
Prov. & W/O (Net) 57.25 45 43.02
P/L in Forex -20.44 -2.18 0
Fin. Lease & Rental Chrgs 0 0 0
Others 0.83 -5.22 -0.03
Total Adjustments (PBT & Extraordinary
Items) 265.47 250.13 322.21
Op. Profit before Working Capital Changes 529.63 385.27 522.54
Adjustment For
Trade & 0th receivables -64.22 13.67 24.11
Inventories -33.5 -47.67 12.68
Trade Payables 95.29 74.57 3.92
Others -10.15 -10.3 0
Total (OP before Working Capital
Changes) -12.58 30.27 40.71
Cash Generated from/(used in)
Operations 517.05 415.54 563.25
Interest Paid (Net) 0 0 0
Direct Taxes Paid -38.76 26.5 -44.61
Advance Tax Paid 0 0 0Total-others -38.76 26.5 -44.61
Cash Flow before Extraordinary Items 478.29 442.04 518.64
Extraordinary Items
Payment Towards VRS 0 0 -28.4
Others 0 0 -6.26
NET CASH USED IN INVESTING ACTIVITIES 415.45 159.33
Net Cash Used in Financing Activities -58.15 275.38
-
7/31/2019 Sapm Report (pancholi chirag)
60/67
Net Inc/(Dec) in Cash and Cash
Equivalent 4.69 7.33
Cash and Cash Equivalents at End of the
year 39.51 34.82
Cash flow statement is very useful to know the liquidity position of the
company. Which activity produced how much cash. It bifurcate cash in three ways cash
flow from financing, operation and investing activities.
Net cash used in investing activities in the year 2002-03 was
Rs. 159.33 Crores which was increased to Rs.415.45 crores in the financial year
2003-04. it means company is expanding its capacity and investing in valuableprojects. Net cash used in financing activities was 58.15 Crs . it indicates company
has borrowed from outside in form of debt to invest in new projects. Cash Generated
from Operations was also increased to Rs.517.05 Cr. In the year 2003-04 from
415.54 in the financial year 2002-03. it was increased by 23%.
So, cash flow from operation is increasing which is very good.
The revenue is increasing and profitability is also increasing. on the other handcompanys investment has also increased they are trying to increase their capacity.
-
7/31/2019 Sapm Report (pancholi chirag)
61/67
RATIO ANALYSIS:
Ratios
Profitability Ratios % PeriodEnded
Mar2004(12
Months)
Period EndedMar2003
(12 Months)
Period EndedMar2002
(12 Months)
Period EndedMar2001
(12 Months)
Period EndedMar2000
(12 Months)
Operating Profit Margin 13.26 11.74 15.90 14.20 8.16
Gross Profit Margin 12.61 8.81 11.54 8.85 2.76
Net Profit Margin 4.64 1.59 3.84 2.15 -3.18
Turnover Ratios
Inventory TurnoverRatio
7.54 7.40 7.88 7.07 7.46
Debtor Turnover Ratio 18.01 15.90 12.98 10.40 9.28
Fixed Asset
TurnoverRatio
1.38 1.22 1.27 1.38 1.28
Solvency Ratio
Current Ratio 0.82 0.85 0.94 1.37 1.45
DebtEquity Ratio 0.98 1.30 1.48 1.44 1.27
Interest Covering Ratio 3.88 2.47 2.86 1.96 1.21
Performance Ratio %
Return On Investment 16.00 14.00 18.00 13.00 8.00
Return On Networth 11.00 4.00 11.00 5.00 -7.00
Dividend Yield 0.40 0.25 0.30 0.20 0.09
Debt Equity Ratio 98.00 130.00 148.00 144.00 127.00
-
7/31/2019 Sapm Report (pancholi chirag)
62/67
PROFIT AND LOSS A/C:
Profit & Loss Accounts (Rs.in Millions)
. Period
EndedMar2004
(12Mnts.)
% Period
EndedMar2003
(12Mnts.)
% Period
EndedMar2002
(12Mnts.)
%
Sales 3,2839.80 +97.31 2,8944.10 +98.21 2,8106.30 +9
Other Income 908.10 +2.69 527.00 +1.79 339.60 +
Total Income 3,3747.90 2,9471.10 2,8445.90
Raw Material Cost 1,2183.00 +36.10 6870.90 +23.31 6960.60 +2
Excise 6150.40 +18.22 5013.80 +17.01 4292.80 +1
Other Expenses 1,0152.90 +30.08 1,3662.00 +46.36 1,2384.60 +4Operating Profit 5261.60 +15.59 3924.40 +13.32 4807.90 +1
Interest Name 1121.70 +3.32 1373.00 +4.66 1564.70 +
Gross Profit 4139.90 +12.27 2551.40 +8.66 3243.20 +1
Depreciation 2071.80 +6.14 1941.10 +6.59 1816.70 +
Profit Bef. Tax 2068.10 +6.13 610.30 +2.07 1426.50 +
Tax 543.20 +1.61 150.90 +0.51 347.00 +
Net Profit 1524.90 +4.52 459.40 +1.56 1079.50 +
Other Non-Recurring Income 477.50 +1.41 579.50 +1.97 224.80 +
Reported Profit 2002.40 +5.93 1038.90 +3.53 1304.30 +Equity Dividend 708.80 +2.10 427.30 +1.45 512.40 +
-
7/31/2019 Sapm Report (pancholi chirag)
63/67
BALANCE SHEET:
Balance Sheet (Rs.in Millions)
LIABILITIES
Period
EndedMar2004
Period
EndedMar2003
Period
EndedMar2002
Share Capital 1,779.40 1,711.40 1,710.50
Reserves & Surplus 11,757.90 9,056.00 8,488.20
Net Worth (1) 13,537.30 10,767.40 10,198.70
Secured Loans (2) 10,401.30 12,874.20 11,054.00
Unsecured Loans (3) 2,871.10 1,173.30 4,048.70
Total Liabilities (1+2+3) 26,809.70 24,814.90 25,301.40
ASSETSPeriodEnded
Mar2004
PeriodEnded
Mar2003
PeriodEnded
Mar2002
FIXED ASSETS
Gross Block 37,897.50 36,369.90 33,260.60
(-) Acc. Depreciation 14,141.40 12,684.30 11,069.60
Net Block (A) 23,756.10 23,685.60 22,191.00
Capital Work in Prgs. (B) 1,161.00 981.70 1,245.70
Investments (C) 3,757.40 1,277.70 1,753.40
CURRENT ASSETS, LOANS & ADVS.
Inventories 3,780.10 3,453.90 3,001.20
Sundry Debtors 1,823.70 1,820.90 2,165.00
Cash And Bank< 395.10 348.20 274.90
Loans And Advances 4,352.10 3,726.10 3,719.60
(i) 10,351.00 9,349.10 9,160.70
Current Liab. & Provs.
Current Liabilities 10,939.60 9,825.30 8,712.70
Provisions 1,625.40 1,175.40 1,072.60
(ii) 12,565.00 11,000.70 9,785.30
Net Curr. Assets (i - ii) (D) -2,214.00 -1,651.60 -624.60
Misc. Expenses (E) 349.20 521.50 735.90
Total Assets (A+B+C+D+E) 26,809.70 24,814.90 25,301.40
-
7/31/2019 Sapm Report (pancholi chirag)
64/67
JAIPRAKASH
BASIC INFORMATION:
NAME: Jaiprakash Associates Ltd.
Incorporation year 1996
Ownership Jaiprakash Group
Main activity Ordinary Portland cement
HISTORY
Jaiprakash Associates (JAL), promoted by erstwhile Jaiprakash
Industries was incorporated on 15th Nov. 1995 under the name Bela Cement. Its name
was changed to Jaypee Rewa Cement w.e.f 30th Aug 2000 and then to Jaypee Cement
w.e.f 3rd Jan 2002. The company was a wholly owned subsidiary of erstwhile Jaiprakash
Industries and was engaged in manufacturing and marketing of cement.
Pursuant to the Scheme of Amalgamation of erstwhile Jaiprakash
Industries with the company, the name has been changed to present one w.e.f 11th March
2004. JAL is presently engaged in the business of manufacturing and marketing of
cement, construction of infrastructure projects like Dams, Barrages, Tunnels,
Underground Power Houses, Highways/Express way etc. and Hoteliering.
-
7/31/2019 Sapm Report (pancholi chirag)
65/67
BOARD OF DIRECTORS:
NAME POSITION
Jaiprakash Gaur CHManoj Gaur MD
P V Vora Director
Ranvijay Singh Director
Rahul Kumar Director
V K Jain Director
R S Kuchhal VP & Secretary
EQUITY HOLDING INFORMATION:
Type/Name of holder No of shares % of total shares
-
7/31/2019 Sapm Report (pancholi chirag)
66/67
INDIAN PROMOTERS
Jaypee Ventures Ltd 4,74,32,830 26.92
Jaiprakash Enterprises Ltd 1,17,24,262 6.65
FII'S
GMO Emerging Markets Fund 1,46,35,020 8.31
Merrill Lynch Capital Markets Espana
SA SVB
46,93,921 2.66
Arisaig Partners (Asia) Pte Ltd A/C
Arisaig Fund Ltd
40,00,000 2.27
UBS AG A/c Long - Term India
Investments Fund Ltd
18,29,784 1.04
PRIVATE CORPORATE BODIES
HB Stockholding Ltd 29,32,135 1.66
Har Sai Investments Ltd 22,40,267 1.27
Matchless Investments Ltd 19,20,000 1
ANY OTHER
Shares in transit / Pool a/c 16,62,592 0.94
Jaiprakash is fundamentally strong company. When you see its equityholding information you will find that about 15% of its total shares are held by FIIs.
foreign institution put trust on this company .about 27% of holdings are with Jaypee
Ventures Ltd and 7% with Jaiprakash Enterprises Ltd.
BALANCE SHEET
Annual Unaudited Results (Rs. in Millions)
.Period Ended
Mar2004(12 Months)
Period EndedMar2003
(12 Months)% Change
Sales Turnover 2,3860.00 2,5150.00 -5.13
Other Income 1320.00 880.00 + 50.00
Total Income 2,5180.00 2,6030.00 -3.27
-
7/31/2019 Sapm Report (pancholi chirag)
67/67
Total Expenditure 1,9190.00 2,0520.00 -6.48
Operating Profit 5990.00 5510.00 + 8.71
Interest 2050.00 2050.00 0.00
Gross Profit 3940.00 3460.00 + 13.87
Depreciation 1270.00 1080.00 + 17.59Tax 970.00 1260.00 -23.02
ReportedPAT 1700.00 1120.00 + 51.79